Importantly, these findings suggest that anti-AR therapy may be biased in favor of ccRCC patients with a propensity for lung metastasis and combining anti-AR and anti-VEGF-C therapy should be better to treat this metastatic ccRCC. This evidence concerns the gene AR and nonpapillary renal cell carcinoma.